24 results
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals, Inc.
25 Jul 24
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
6:04am
.”
Ipsen’s deep heritage and expertise in oncology means we can accelerate the delivery of this innovation as teams focus on regulatory activities outside … .
Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals, Inc.
24 Apr 24
Regulation FD Disclosure
8:01am
, study investigators, non-profit organizations, and advocacy groups, for their collaboration and support as we strive to close the innovation gap
S-8
EX-99.1
hc1i5ujow8x96mj251
4 Jan 24
Registration of securities for employees
4:06pm
8-K
EX-14.1
ezppdhahc9dujo
8 Dec 23
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:05pm
S-8
EX-99.1
jwb 3fud06hvse
31 Oct 22
Registration of securities for employees
4:07pm
10-K
j3ejjq1bk
7 Mar 22
Annual report
7:36am
10-Q
90otoiaw
10 Aug 21
Quarterly report
5:26pm
424B4
100gopvc l0ot
27 May 21
Prospectus supplement with pricing info
4:18pm
S-1/A
EX-10.2
c5tj4t
24 May 21
IPO registration (amended)
6:16am